Vermorken JB - Search Results

1

Pignata S, Vermorken JB. Pignata S, et al. Among authors: vermorken jb. Crit Rev Oncol Hematol. 2004 Jan;49(1):77-86. doi: 10.1016/s1040-8428(03)00100-8. Crit Rev Oncol Hematol. 2004. PMID: 14734157 Review.

2

Induction chemotherapy with cisplatin and continuous infusion 5-fluorouracil in locally far-advanced head and neck cancer.

Verweij J, de Jong PC, de Mulder PH, van der Broek P, Alexieva-Figusch J, van Putten WL, Schornagel JH, Ravasz LA, Snow GB, Vermorken JB. Verweij J, et al. Among authors: vermorken jb. Am J Clin Oncol. 1989 Oct;12(5):420-4. doi: 10.1097/00000421-198910000-00012. Am J Clin Oncol. 1989. PMID: 2801602

3

Carboplatin in combination therapy for ovarian cancer.

ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Neijt JP, George M, Guastalla JP, Veenhof CH, Rotmensz N, Dalesio O, Vermorken JB. ten Bokkel Huinink WW, et al. Among authors: vermorken jb. Cancer Treat Rev. 1988 Jun;15 Suppl B:9-15. doi: 10.1016/0305-7372(88)90030-8. Cancer Treat Rev. 1988. PMID: 3135934 Clinical Trial.

4

Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian Cancer.

van der Burg ME, ten Bokkel Huinink WW, Vriesendorp R, van Oosterom AT, Neijt JP, Vermorken JB, van Putten WL, Kooiman A. van der Burg ME, et al. Among authors: vermorken jb. Eur J Cancer Clin Oncol. 1987 Jul;23(7):997-8. doi: 10.1016/0277-5379(87)90348-8. Eur J Cancer Clin Oncol. 1987. PMID: 3666002

5

Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.

Giaccone G, Huizing M, ten Bokkel Huinink W, Koolen M, Postmus P, van Kralingen K, van Zandwijk N, Vermorken J, Beijnen J, Dalesio O, et al. Giaccone G, et al. Semin Oncol. 1994 Oct;21(5 Suppl 8):34-8. Semin Oncol. 1994. PMID: 7939761 Clinical Trial.

6

Consolidation therapy in patients with advanced ovarian cancer.

Vermorken JB. Vermorken JB. Eur J Gynaecol Oncol. 1994;15(1):7-13. Eur J Gynaecol Oncol. 1994. PMID: 8206075 Review.

7

Advanced ovarian cancer. Carboplatin versus cisplatin.

Vermorken JB, ten Bokkel Huinink WW, Eisenhauer EA, Favalli G, Belpomme D, Conte PF, Kaye SB. Vermorken JB, et al. Ann Oncol. 1993;4 Suppl 4:41-8. Ann Oncol. 1993. PMID: 8312200 Review.

8

The role of anthracyclines in second-line therapy of ovarian cancer.

Vermorken JB. Vermorken JB. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:178-84. doi: 10.1111/j.1525-1438.2003.13364.x. Int J Gynecol Cancer. 2003. PMID: 14656277 Review.

9

Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy.

Saba NF, Mody MD, Tan ES, Gill HS, Rinaldo A, Takes RP, Strojan P, Hartl DM, Vermorken JB, Haigentz M Jr, Ferlito A. Saba NF, et al. Among authors: vermorken jb. Crit Rev Oncol Hematol. 2017 Jul;115:50-58. doi: 10.1016/j.critrevonc.2017.04.011. Epub 2017 Apr 27. Crit Rev Oncol Hematol. 2017. PMID: 28602169 Review.

10

High-dose intensity regimens with epirubicin in ovarian cancer.

Vermorken JB. Vermorken JB. Pathol Biol (Paris). 1992 Nov;39(9):833. Pathol Biol (Paris). 1992. PMID: 1538894 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

557 results

Search Page